Cohance Lifesciences Ltd
Cohance Lifesciences Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY27 growth expected to return from the second half, with Q1 being weak and Q2 stable. Growth is expected to return from the second half of FY27, with Q1 FY27 being weak in both revenue and EBITDA due to revenue schedules skewed towards H2 and cost pressures (Page 4).
From Cohance Lifesciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 growth expected to return from the second half, with Q1 being weak and Q2 stable.
- Recovery order: API segment first, followed by CDMO and Specialty Chemicals.
- Growth driven by execution on existing programs, customer conversions, reloads, and improved asset utilization.
- Pipeline strengthened with 10 Phase 3 programs; 2 programs recently commercialized and others progressing well.
- New molecule launches ongoing, with 4 commercial launches planned across FY26 and FY27.
- Increase in customer base and diversification efforts underway to reduce dependency on a few molecules.
- Expansion in ADC, oligonucleotide, and small molecule capabilities expected to drive future growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Cohance Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex during FY26 was INR 2.15 billion, focused on ADC, oligonucleotides, manufacturing infrastructure, and quality systems.
- Capex spend expected to be nearly INR 3 billion in FY27.
- Investment ongoing in NJ Bio to support bioconjugation programs for Phase 1 and Phase 2; implementation expected to take about one year plus validation time, with recovery in over two years.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Cohance Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company reported an active and growing order book, especially in the Phase 1 and Phase 2 programs with strong quality customers.
- The Phase 3 pipeline increased to 10 programs, with two programs progressing toward commercialization.
- They experienced healthy reload conversion above 90% and good new business conversions with innovator pharma and biotech customers.
- The CDMO business is focusing on expanding the customer base and onboarding later-phase projects to accelerate revenue recovery.
- FY27 is seen as a qualification and readiness year for parts of the portfolio, with supplies expected to build as customer programs progress.
2 more points management made on order book & pipeline
Cohance Lifesciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹619 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cohance Life's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Cohance Lifesciences Ltd Q4 FY26 results?
FY27 growth expected to return from the second half, with Q1 being weak and Q2 stable. Growth is expected to return from the second half of FY27, with Q1 FY27 being weak in both revenue and EBITDA due to revenue schedules skewed towards H2 and cost pressures (Page 4).
What is Cohance Lifesciences Ltd share price analysis?
Cohance Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 152.6 with a market cap of ₹16,429 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cohance Lifesciences Ltd planning capital expenditure?
Capex during FY26 was INR 2.15 billion, focused on ADC, oligonucleotides, manufacturing infrastructure, and quality systems.
Keep Cohance Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.